Avadel's Once-Nightly Narcolepsy Drug Hits Three Co-Primary Endpoints in Late-Stage Trial

Dublin, Ireland-based Avadel Pharma announced positive topline data from its pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. Company shares rocketed 30% in premarket trading in response to the news.